Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (NYSE: LYEL) is a clinical-stage biotechnology company developing novel T-cell therapies for solid tumors and hematologic malignancies through proprietary genetic/epigenetic reprogramming technologies. This page serves as the definitive source for verified company announcements, research breakthroughs, and regulatory developments.
Investors and researchers will find timely updates on Lyell's innovative pipeline including CAR T-cell candidates LYL797 and LYL119, tumor-infiltrating lymphocyte therapy LYL845, and dual-targeting IMPT-314 from the ImmPACT Bio acquisition. Our curated news collection covers essential developments across three key areas:
Clinical Trial Milestones: Phase 1/2 updates, patient enrollment progress, and safety/efficacy data disclosures
Research Innovations: Peer-reviewed study publications, ASCO/SITC presentations, and new patent filings
Strategic Developments: Manufacturing partnerships, leadership appointments, and regulatory pathway updates
Bookmark this page for direct access to Lyell's official press releases, SEC filings, and scientifically validated progress reports. Check regularly for updates on technologies addressing T-cell exhaustion and improving durable response rates in cancer immunotherapy.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported financial results for Q4 and full year 2022, highlighting a net loss of $8.4 million for Q4 and $183.1 million for the year, but significantly increased revenue of $48.4 million for Q4 and $84.7 million for the year, up from $2.8 million and $10.7 million in 2021. The company's cash position stands at $710.3 million as of December 31, 2022, supporting ongoing clinical trials and a robust pipeline. Lyell initiated Phase 1 trials for two product candidates targeting solid tumors and presented promising nonclinical data at several conferences. The company expects initial clinical data from LYL797 and LYL845 in 2024.
Lyell Immunopharma will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 pm PT. The presentation will showcase Lyell's pipeline, including CAR T cell product candidates LYL797 and LYL845, both in Phase 1 trials, and the innovative LYL119 targeting ROR1. Key technologies will be highlighted, such as NR4A3 gene knockout and Stim-RTM for enhanced CAR T cell activity. A live webcast will be available on the company’s website with a 30-day replay.
Lyell Immunopharma (Nasdaq: LYEL) has appointed Lynn Seely, MD, as president & CEO, succeeding Liz Homans, who transitions to a consulting role until June 2024. Dr. Seely brings extensive biopharmaceutical leadership experience, having previously served as CEO of Myovant Sciences, where she successfully launched therapies for cancer and women's health. Under her leadership, Lyell aims to advance its clinical-stage programs and enhance its T-cell reprogramming technologies to improve treatment outcomes for solid tumors.
FAQ
What is the current stock price of Lyell Immunopharma (LYEL)?
What is the market cap of Lyell Immunopharma (LYEL)?
